CapsoVision (CV) vs InMode (INMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CapsoVision (CV) has outperformed InMode (INMD) over the past year, gaining 16.8% versus a loss of 11.7%. InMode is the larger company by market cap ($714.7 million vs $327.6 million), about 2.2 times the size, while CapsoVision is growing revenue faster (+15.3% vs -6.2%). InMode converts more of its revenue into profit, with a net margin of 25.3% versus -186.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | INMD |
|---|---|---|
| Share price | $6.11 | $12.42 |
| Market cap | $327.56M | $714.70M |
| 1-day change | -3.17% | -2.20% |
| YTD return | -42.84% | -15.45% |
| 1-year return | +16.83% | -11.66% |
| 5-year return | — | -85.21% |
| P/E ratio (TTM) | — | 10.44 |
| Forward P/E | — | 9.15 |
| EPS (TTM) | $-0.42 | $1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.55M | $370.50M |
| Revenue growth (YoY) | +15.29% | -6.16% |
| Net income (latest FY) | $-25.32M | $93.83M |
| Gross margin | 52.92% | 78.54% |
| Operating margin | -188.25% | 23.05% |
| Net margin | -186.77% | 25.33% |
| 52-week high | $15.37 | $16.67 |
| 52-week low | $4.50 | $12.40 |
| Distance from 52-week high | -60.25% | -25.49% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +55.48% | +18.12% |
| Average volume | 173.59K | 529.24K |
| Shares outstanding | 53.61M | 57.54M |
| Employees | 99 | 660 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- InMode is about 2.2 times larger than CapsoVision by market value ($714.70M vs $327.56M).
- CV has outperformed INMD by 28.5 percentage points over the past year.
- InMode is more profitable, keeping 25.3 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
- CapsoVision grew revenue faster in its latest fiscal year (+15.29% vs -6.16%).
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
CV vs INMD FAQ
Which is bigger, CapsoVision or InMode?
InMode (INMD) is larger, with a market capitalization of $714.70M compared with $327.56M for CapsoVision (CV).
Which stock has performed better over the past year, CV or INMD?
CV returned +16.83% over the past 12 months, compared with -11.66% for INMD (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and InMode in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.